Lantern Pharma (LTRN) Stock Overview
Focuses on the discovery and development of oncology drug in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LTRN Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Lantern Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$5.74 |
| 52 Week Low | US$2.53 |
| Beta | 1.52 |
| 1 Month Change | -15.18% |
| 3 Month Change | -17.63% |
| 1 Year Change | -40.75% |
| 3 Year Change | -47.42% |
| 5 Year Change | -83.67% |
| Change since IPO | -80.94% |
Recent News & Updates
Recent updates
Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely
Nov 21
Will Lantern Pharma (NASDAQ:LTRN) Spend Its Cash Wisely?
Feb 21Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Nov 05Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Shareholder Returns
| LTRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.4% | 0.8% | 1.4% |
| 1Y | -40.7% | 29.0% | 13.2% |
Return vs Industry: LTRN underperformed the US Biotechs industry which returned 29.7% over the past year.
Return vs Market: LTRN underperformed the US Market which returned 14% over the past year.
Price Volatility
| LTRN volatility | |
|---|---|
| LTRN Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LTRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LTRN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 24 | Panna Sharma | www.lanternpharma.com |
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers.
Lantern Pharma Inc. Fundamentals Summary
| LTRN fundamental statistics | |
|---|---|
| Market cap | US$32.55m |
| Earnings (TTM) | -US$18.92m |
| Revenue (TTM) | n/a |
Is LTRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LTRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.92m |
| Earnings | -US$18.92m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LTRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 11:42 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lantern Pharma Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chad Messer | Lake Street Capital Markets, LLC |
| Ashok Kumar | ThinkEquity LLC |